Tibsovo: Indication, Usage, Side-effects & Price

 The brand name medicine Tibsovo contains the active salt ivosidenib. It’s in a group of medicines named IDH1 inhibitors. (A medicine class is a group of drugs that acts identically.) Tibsovo is supplied as a tablet that needs to be swallowed. Tablets are commercially available in one strength: 250 milligrams (mg). You’ll likely take Tibsovo tablets once per day.

Indications of Tibsovo:

 Tibsovo is a once-daily prescription therapeutic drug used to treat adult patients with mutation IDH1 with:

Newly Diagnosed Acute Myeloid Leukemia AML):  In addition with azacitidine or as a single medicine (monotherapy) for newly diagnosed AML in adults 75 or older.

Relapsed or refractory AML: For adults with relapsed or refractory AML.

Cholangiocarcinoma (bile duct cancer): Patients who have received previous therapy and whose cancer has progressed.

The proposed dose of Tibsovo for AML and bile duct cancer is 500 mg orally once daily until the disease is progressive or in case of unacceptable toxicity. Administer it either with or without a meal. Do not use it with a high-fat food/meal because there may be a risk of an increase in ivosidenib concentration. It is not advisable to split or crush the tibsovo 250 mg tablets. Administer the medicine orally at about the same time each day. 

Side-effects of Tibsovo:

As per reports the most common side effects of AML are arthralgia, fatigue, leukocytosis, rash, cough, edema, diarrhea, nausea, dyspnea, mucositis, electrocardiogram QT prolonged, decreased appetite, myalgia, constipation, and pyrexia.

The most common side effects in patients with cholangiocarcinoma (bile duct cancer) are abdominal pain, fatigue, nausea, decreased appetite, rash, diarrhea, cough, ascites, anemia, and vomiting.

Cost of Tibsovo:

Tibsovo is an advanced imported medicine yet to be approved in India. It is natural for patients to look for the cost of Tibsovo in India. This medication should be officially procured through trusted and authorized importers like THE INDIAN PHARMA (TIP). For more inquiry, Call/WhatsApp: +91 9310090915, and we will help you calculate the total Tibsovo cost to buy this therapeutic product online legally.

Reference:

https://www.tibsovo.com/

What is T-cell Acute Lymphoblastic Leukemia

 T-ALL or T-cell acute lymphoblastic leukemia is a sort of acute lymphoblastic leukemia meaning that it is invasive and spreads rapidly. It impacts the lymphoid-cell-developing stem cells, in specific a type of white blood cell named T lymphocytes as opposed to acute lymphoblastic leukemia which commonly impacts B lymphocytes.

In this blood cancer, the immature white blood cells (WBCs) deposit in the bone marrow and eliminates normal white blood cells (WBCs), weakening the defense system. The cells may also deposit in the liver, lymph nodes, and spleen.

Causes and Risk Factors of T-ALL:

In maximum cases of T-cell acute lymphoblastic leukemia, there is no exact cause but it is necessary to understand that T-ALL neither is a complication that can be caught from someone else (contagious) nor passed on from a parent to a child (inherited)

Rick factors:

Age: most types of leukemia are so common in older individuals. The major exception to this is ALL, in which the highest incidence is in children, aged between about 2 to 5 years. T-ALL is most commonly found in slightly older children.

Being male: T-cell acute lymphoblastic leukemia (T-ALL) affects men more than women of all ages.

Signs and Symptoms of T-ALL:

There are no exclusive signs or symptoms which can help make T-ALL diagnosis easy. The most commonly reported signs and symptoms of T-ALL are caused by the bone marrow being not able to make adequate normal blood cells.

• Anaemia (because of lack of red blood cells)
• Tiredness, weakness, shortness of breath, palpitations, light-headedness
• Infections (because of lack of normal white blood cells)
• Infections are more frequent, more severe, and last longer
• Malaise, fever (general feeling of illness), and sweats
• Purpura (small bruises on the skin), bleeding gums, nosebleeds
• Bleeding and bruising (because of lack of platelets)

Other commonly reported signs and symptoms include:

T-ALL oftentimes causes swollen lymph nodes in the mediastinum (a middle part of the chest) which may impact breathing or the circulation

Drug Therapy for T-cell Acute Lymphoblastic Leukemia (T-ALL):

The drug Atriance contains the active substance Nelarabine. It is specifically licensed for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) that doesn’t respond to or relapses following initial therapy. It is commercially available as a 250 mg/50 mL (5 mg/mL) vial. Atriance 250 mg/50 mL can be effective, but about 15 % of individuals who receive treatment may develop neurotoxicity, which can cause serious and irreversible side effects. 

Tukysa: Warnings & Precautions

The therapeutic product Tukysa, containing the active substance Tucatinib, is a film-coated tablet that falls under the classification of tyrosine kinase inhibitors. Tukysa is commercially supplied as a 150 mg or 50 mg film-coated tablet. Seattle Genetics is credited for the medicine development and efforts in securing regulatory approval. 

Tukysa is a relatively new therapeutic product yet to be authorized in several world regions, including India. Tukysa cost in India depends on its availability and the regulatory constraints noted by the country of import.

Tukysa has been approved with trastuzumab and capecitabine to treat adult individuals with unresectable or metastatic HER2+ breast cancer, including those with brain metastases regimens previously treated with one or more anti-HER2-based.

The medicine is also authorized in conjunction with medicine trastuzumab to treat adult individuals with RAS wild-type HER2+ unresectable or metastatic colorectal cancer that has proceeded after treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.

Tukysa is available on prescription only. The recommended dosage of Tukysa tablets is 300 mg, taken orally twice daily in 21-day cycles. 

Warnings and Precautions:

Diarrhea: The medication Tukysa can be responsible for causing severe diarrhea, including hypotension, 

dehydration, and acute kidney injury. In case diarrhea is reported, administer anti-diarrheal medicines. Perform diagnostic tests to exclude other potential causes of diarrhea. On behalf of the seriousness of diarrhea, doses can be interrupted, scaled down, or permanently stopped.

Hepatotoxicity: This therapeutic product can be responsible for causing severe hepatotoxicity. Monitor AST, ALT, and bilirubin before treatment and every 3 weeks during treatment. On behalf of the severity of hepatotoxicity, Tucatinib doses can be interrupted, scaled down, or permanently stopped.

Embryo-Fetal Toxicity: This tyrosine kinase inhibitor can cause fetal harm. Instruct pregnant women and women of reproductive age about the probable hazard to a fetus. Females of reproductive capacity and male patients with female partners of reproductive age should use suitable contraception during Tukysa therapy and at least 7 days after the eventual dose.

Note: The price of Tukysa is economical and one can order this medicine from multiple pharmaceutical suppliers in India. 

Reference: https://www.seagen.com/medicines/tukysa